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Tenofovir HIV prevention study 
• Groups at high-risk of contracting HIV 
• Tenofovir versus “placebo”  
• HIV risk-reduction counseling, male condoms, treatment 
for other sexually transmitted infections  
• Gilead Sciences, Inc. agrees to provide drug at cost to 
developing countries  
• Controversy erupted over several issues, including the 
failure of researchers and sponsors to provide life-long 
ART to research subjects who contract HIV  
• Trials in Cambodia, Cameroon, Malawi, Nigeria stopped 
Question 
 
 
 
 In an HIV prevention trial, do researchers and sponsors 
in fact have a moral obligation to provide life-long ART to 
research subjects who contract HIV? 
Putative bases for a moral obligation 
1. Contracting HIV is a research-related injury and 
compensation must be provided 
 
2. The ethical principle of beneficence requires that we 
maximize benefits to research subjects 
 
3. Infected research subjects contribute uniquely and 
reciprocity requires that they receive something in 
return 
 
4. Equality requires that HIV-infected subjects be treated 
regardless of their geographical location 
Argument 3: Reciprocity 
• The argument from reciprocity 
• UNAIDS (2004): 
– “With respect to the principle of reciprocity, subjects 
who become infected contribute importantly to the 
trial. Without such data, an efficacy trial could draw no 
conclusions about the intervention studied. People 
who contribute to this effort deserve something in 
return.” 
• Presumably, this “something in return” is life-long ART  
Argument 3: Reciprocity 
• Research subjects contribute equally  
• Rewarding only those who contract HIV fails to reward 
all who “contribute to this effort”  
 
• Macklin (2005): 
– “It is certainly true that all research subjects contribute 
to the success of a trial. However, those who become 
infected contribute in a unique way. They are the only 
subjects whose contribution makes it possible to draw 
any precise conclusions about the efficacy (or lack 
thereof) of a preventive vaccine trial.”  
  
Logic of efficacy 
 A. Intervention effective if and only if πpi > πii 
 B. Intervention effective if and only if (1-πii) > (1-πpi) 
 A is logically equivalent to B 
Study 
population at 
high risk of 
HIV infection 
Group 
receiving 
intervention 
Group 
receiving 
placebo 
Infected (πii) 
Not infected (1-πii) 
Infected (πpi) 
Not infected (1-πpi) 
Argument 3: Reciprocity 
• The determination of the efficacy of an intervention rests 
no more on those who become HIV infected than those 
who do not 
• The contribution to the determination of efficacy of those 
who do and those who do not become infected is equal  
• According to the principle of reciprocity, either no group 
is deserving of reward, or both groups are  
 
• Undermines that claim based on reciprocity that those 
who contract HIV in the study should receive life-long 
ART 
Question 
 
 
 
 If the moral basis for the provision of life-long ART to 
persons who contract HIV in a prevention trial is not 
moral obligation, then what is it?  
Moral negotiation 
• Ethical principal of respect for communities (Weijer C, 
Emanuel EJ. Science 2000) 
• Community-researcher partnership 
• Community should 
– Have input on study question 
– Influence on study design 
– Share in study benefits 
• Health priorities and values vary from one community to 
the next 
• Study design and benefit sharing is a matter of moral 
negotiation between community and researcher/sponsor 
Moral negotiation 
• Community values and health priorities drive what 
constitutes appropriate benefits 
 
– Community A: Clean well and a medical clinic to meet 
the basic health needs of members  
– Community B: Enhanced access to basic HIV 
treatment for all members  
– Community C: Advanced ART  
 
• To impose a predetermined research question, study 
design, or benefits package seems paternalistic 
Moral negotiation 
 
   “[O]nly the host population can determine the value of 
the benefits for itself. Outsiders are likely to be poorly 
informed about the health, social, and economic 
context in which the research is being conducted, and 
they are unlikely to fully appreciate the importance of 
the proposed benefits to the population.” 
 
   Participants in the Conference on Ethical Aspects of 
Research in Developing Countries (2001)  
Learning from tenofovir 
• Claims of moral obligation are unsupported currently by 
sound moral argument 
 
• Moral negotiation  
– Reduces the chance of polarization of positions  
– Allows for middle-ground solutions  
– Allows others to be present at the table  
– Allows for solutions that fit the particular circumstances of the 
community in question  
 
• Protect and empower communities in research 
• Allow much needed research with communities at risk to 
develop more effective HIV prevention strategies 
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Argument 1: Injury 
• Argument from research-related injury 
• Contracting HIV in an HIV prevention study is a research 
related injury and thus compensation, including medical 
treatment, must be provided 
• Research subjects have done their share by participating 
in research 
• When there is serious harm caused by the research it 
would be unjust for them to shoulder the burden of such 
harms 
• Rather society has an obligation to compensate such 
individuals and provide them with needed medical care 
Argument 1: Injury 
• Childress (1976): 
– “(1) The injured party accepts or is compelled to 
accept a position of risk (‘positional risk’). Objective 
risks that the injured party would not have otherwise 
encountered emerge from the position accepted.  
– (2) The activity is for the benefit of society, although 
any particular individual’s motives may not be to 
benefit the society... 
– (3) Society, through the government or its agencies, 
conducts, sponsors, or mandates the practice in 
question.”  
Argument 1: Injury 
• HEW Secretary’s Task Force on the Compensation of 
Injured Research Subjects (1977): 
– “Harm, disability or death suffered by a subject at risk 
of biomedical and behavioral research…where such 
injury is (1) proximately caused by such research, and 
(2) on balance exceeds that reasonably associated 
with such illness from which the subject may be 
suffering, as well as with treatment usually associated 
with such illness at the time the subject began 
participation in the research.” 
Argument 1: Injury 
• If a research subject becomes infected due to 
administration of a vaccine contaminated with HIV or via 
contaminated needles, then the harm of HIV infection is 
proximately caused by study participation 
• However, in most cases subjects in prevention trials will 
become infected because of their membership in a high-
risk group and not because of trial participation.  
• Since trial participation in these cases is not the 
proximate cause of the harm, there is no research-
related injury and no basis for a claim of compensation.  
Argument 2: Benefit 
• Argument from beneficence 
• UNAIDS (2004):  
– “Beneficence proposes to maximize benefits and 
minimize harm to subjects. The obligation to 
maximize benefits goes beyond the design of a trial 
and the conduct of a trial itself.”  
• Providing treatment for HIV maximizes benefit 
• Therefore there is a moral obligation to provide it for 
those who develop the infection during the trial.  
 
Argument 2: Benefit 
• An unrestricted  moral obligation to “maximize benefits” 
leads to an unstoppable chain of demands upon 
researchers:  
– Treating HIV for free is good 
– Building hospitals and staffing them in perpetuity with 
free doctors and medical supplies is better 
– Making everyone not merely healthy but rich and 
happy is best of all.  
• Right action, according to this view, comes with a hefty 
price tag. 
Argument 2: Benefit 
• Macklin (2005): 
– “A principle of health maximization is not intended to 
lead to an unstoppable chain of claims. Every 
principle requires interpretation and specifying criteria 
for its correct—and often limited—application. A full 
account of what is owed to research subjects and to 
others in the community or country would have to 
spell out such criteria and limits.”  
• We agree and await just such a specification 
• Until that point the argument must be rejected. 
Argument 4: Equality 
• Argument from equality 
• UNAIDS (2004): 
– “Justice, as a basis for ethical obligation to provide 
high standard treatment and care, can be interpreted 
in a number of ways. Justice as equality is based on 
the notion that subjects in resource-poor countries 
who become infected are similar in relevant aspects 
to subjects in industrialized countries and therefore an 
obligation exists to provide equal treatment to all 
participants in trials, regardless of their geographical 
location.” 
Argument 4: Equality 
• One might grant the interpretation as plausible yet deny 
that researchers or their sponsors have any obligation to 
provide HIV treatment in developing countries.  
• In developed countries, people who become infected 
during participation in an HIV prevention trial do receive 
treatment, but that treatment is provided through state or 
private insurance and not by researchers or sponsors.  
• The claim made above is unhelpfully free-floating.  
Argument 4: Equality 
• Equality does not merely hold across international 
boundaries; it also holds within states.  
• If HIV treatment is generally not available in an 
undeveloped country, but it is provided to those who 
become infected in an HIV prevention trial, is this not a 
violation of equality?  
• Slack (2005):  
– “It could be argued that inequalities in access to 
treatment within a community are as unjust as 
inequities ‘across the waters’ or between 
collaborating nations, or at least that it is logically 
inconsistent to use justice-based arguments to 
introduce further local inequalities.”  
